Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002211 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients
A NA study of HIV Infections, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00002211: Completed NA study of HIV Infections, sponsored by Pharmacia and Upjohn.
NCT00002211 is a NA study of HIV Infections that has completed, run by Pharmacia and Upjohn. The registered enrollment target is 160 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002211, a NA study of HIV Infections, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).
Conditions Studied
Interventions
- DRUG Stavudine
- DRUG Didanosine
- DRUG Nelfinavir mesylate
- DRUG Delavirdine mesylate
Study Locations (1)
New Jersey
- Pharmacia & Upjohn - Peapack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Phase | NA |
What the finished NCT00002211 record still lists
NCT00002211 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (64% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Stavudine is the first listed.
NCT00002211 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00002211 about?
NCT00002211 is a clinical study titled "Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients". The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).
What is the current status of trial NCT00002211?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants.
What conditions does trial NCT00002211 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002211?
The interventions under investigation include: Stavudine (DRUG), Didanosine (DRUG), Nelfinavir mesylate (DRUG), Delavirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002211?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002211 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002211's enrollment target sits among peer trials
160 204th of 542 higher than 338 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)